摘要
α受体阻滞剂是治疗高血压的经典药物,具有不可替代的临床应用价值。《α受体阻滞剂降压治疗中国专家共识》作为国内首部α受体阻滞剂共识,详细介绍了α受体阻滞剂在难治性高血压、合并良性前列腺增生、血糖血脂异常、慢性肾脏病等高血压患者中的应用,以及在高血压急症、嗜铬细胞瘤、原发性醛固酮增多症筛查等疾病治疗中的疗效与安全性,旨在为α受体阻滞剂的合理应用提供指导。
α-blocker is a classic antihypertensive drug class and indispensable in the management of hypertension.This Chinese experts consensus document is the first that summarizes evidence and provides recommendations on the efficacy and safety of α-blockers in the treatment of refractory hypertension,hypertension with comorbid benign prostatic hyperplasia,dyslipidemia and hyperglycemia,and chronic kidney disease,hypertensive emergency,pheochromocytoma and primary aldosteronism under screening.It also attempts to provide guidance for the optimized use of α-blockers in the management of hypertension.
作者
《α受体阻滞剂降压治疗中国专家共识》专家委员会
王继光
The Experts Committee of Chinese experts consensus on the use of α-blockers in antihypertensive therapy
出处
《中华高血压杂志》
CAS
CSCD
北大核心
2022年第5期409-416,共8页
Chinese Journal of Hypertension
关键词
Α受体阻滞剂
高血压
降压治疗
共识
α-blocker
hypertension
antihypertensive treatment
consensus
